A comprehensive view of FDA Drug / Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA accepts for priority review GSK’s application for an expanded indication of Jemperli dostarlimab-gxly plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Published: April 24, 2024 by GSK Group (GlaxoSmithKline)
FDA approves Roche's oral Alecensa for ALK-positive early-stage lung cancer treatment following successful Phase 3 trial; trial results show Alecensa reduced the risk of disease recurrence or death by 76%
Published: April 19, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
FDA grants fast track designation to Asklepios BioPharmaceutical's AB-1002, a gene therapy for adults with non-ischemic cardiomyopathy and Class III heart failure symptoms; the therapy is currently in Phase 2 trials
Published: April 18, 2024 by Bayer AG
IceCure Medical submits final data to the FDA for market authorization for the ProSense cryoablation system to treat early-stage T1 invasive breast cancer; the system treats tumors by freezing them with liquid nitrogen
Published: April 18, 2024 by Zack's Commentary
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for review by the FDA; vaccine aims to provide broad protection against the five most common bacterial groups that cause invasive meningococcal disease
Published: April 16, 2024 by GSK Group (GlaxoSmithKline)

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count